High-density Lipoprotein Cholesterol Levels and Prognosis in Advanced Heart Failure

Background: High-density lipoproteins (HDLs) influence the generation of prostacyclin via cyclooxygenase stimulation. Prostaglandins represent an important compensatory pathway in advanced heart failure (HF). Whether HDL levels discriminate prognosis in HF remains unknown. Methods: We prospectively evaluated the prognostic relationship of HDL levels in severe HF by examining 132 consecutive patients listed for heart transplantation (52 +/- 11 years of age, 80% men, 79% white, mean follow-up 18 months). Using population mean HDL levels (HDL <33 mg/dl [n = 47] vs >= 33 mg/dl [n = 85]), patients were grouped and followed for the primary composite end-points of HF hospitalizations or death, stratified by underlying etiology (non-ischemic, n = 52; ischemic, n = 80). Results: Patients with HDL <33 mg/dl had lower serum sodium (135 vs 137 mEq/liter, p = 0.008), higher total bilirubin (1.3 vs 0.7 mg/dl, p < 0.001) and higher uric acid (7.6 vs; 6.7 mg/dL, p = 0.048) levels, but similar serum creatinine compared with the >= 33 mg/dl HDL group. Survival analysis, using a Cox proportional hazards model, revealed reduced HDL (<33 mg/dl) as the most significant independent predictor of HF hospitalizations or death, independent of underlying etiology. Low-cholesterol and low-density lipoprotein (LDL)-cholesterol alone were not found to be independently predictive Of Outcome. Conclusions: Lower HDL levels correlate with adverse prognosis independent of etiology and predict clinical worsening or death in advanced HE Further study is warranted as to whether these findings represent a clinical marker or suggest a potential therapeutic target. J Heart Lung Transplant 2009; 28:876-80. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.